Respiratory Care: Noninvasive Ventilation and Airway Management Products

Asthma and COPD, the two most prevalent respiratory diseases, affect nearly 600 million people worldwide, with annual mortality rates exceeding 3 million for COPD and 400,000 for asthma. COVID-19 has infected more than 60 million people worldwide, resulting in 1.5 million deaths. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the positive airway pressure (PAP)-based noninvasive ventilation (NIV) and airway management products market, including CPAP and BiPAP devices as well as heat/moisture exchangers (HMEs), humidifiers, and nebulizers (including large- and small-volume nebulizers and nebulizer compressors). This report covers the global market including the US, five major European markets (France, Germany, Italy, Spain, and the UK) for 2019–24. In 2019, combined global sales of the PAP-based NIV products and airway management accessories covered by this report totaled nearly $7bn, with NIV products accounting for more than two-thirds of total sales. Sales are expected to increase at a CAGR of 7.6%, reaching nearly $10bn in 2024. COVID-19 is expected to cause a surge in sales of these products in 2020–21 as less invasive ventilation devices gain popularity in treating patients in respiratory distress, and as demand for airway management accessories such as HMEs, humidifiers, and nebulizers rises with the increase in ventilated patients.